Cancer Family
Benign Nervous System Neoplasm
CI-CAN-00000084Explore in graph →
Non-malignant62 active trials2 evidence items
- NCIt
- C4789
Loading cancer entity…
Cancer Family
CI-CAN-00000084Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT01199978 | Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01419067 | A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection | active not recruiting | Phase 2 | 112 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05684692 | Screening Trial for Pain Relief in Schwannomatosis (STARFISH) | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03962543 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas(ReNeu) | active not recruiting | Phase 2 | 114 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03224767 | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | active not recruiting | Phase 2 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06188741 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1(NF114) | recruiting | Phase 2 | 200 | University of Alabama at BirminghamOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | active not recruiting | Phase 2 | 114 | St. Justine's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 30 | Nationwide Children's HospitalOTHER | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05465174 | Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults(PNOC029) | recruiting | Phase 2 | 57 | Sabine Mueller, MD, PhDOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT06517888 | Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | recruiting | Phase 1 / Phase 2 | 27 | Akouos, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas(NF110) | completed | Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03079999 | Study of Aspirin in Patients With Vestibular Schwannoma | active not recruiting | Phase 2 | 97 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06299891 | Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity | recruiting | Phase 2 | 24 | Seattle Children's HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT03231306 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas(NF108-BINI) | completed | Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT03741101 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib(plexifpc) | unknown | Phase 2 | 15 | Region SkaneOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04163419 | Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis | unknown | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05525273 | Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma(Swecranio) | recruiting | Phase 2 | 25 | Eva Marie Erfurth, MD, PhDOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | terminated | Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT02842723 | Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) | completed | Phase 2 | 33 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04801953 | Nimodipine in Vestibular Schwanommas | unknown | Phase 2 | 30 | Medical University of ViennaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04351373 | Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 | completed | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02849743 | Intranasal Oxytocin in Hypothalamic Obesity | completed | Phase 2 | 18 | Shana McCormack, MDOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02934256 | Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors(Icotinib) | completed | Phase 2 | 10 | Li PengOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03688568 | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01207687 | Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00076102 | Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00021541 | R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 2 | Apr 17, 2018 | clinicaltrials |
| NCT03393689 | RGD PET/MRI in Sporadic Vestibular Schwannoma | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Jan 10, 2018 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials